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Antitrust Considerations in Innovation-Driven Markets
Joseph Kattan*
T he impact of antitrust on innovative activity has never been a more
timely topic than it is today. During the past few years, the federal
antitrust enforcement agencies have taken an interest in competition in
the sphere of innovation as an area with which the antitrust laws
should be concerned. The government has brought several cases over
the past few years based on theories that certain proposed transactions,
usually mergers and acquisitions, would lead to a reduction in innova-
tion activity if allowed to go forward. And two weeks ago, the govern-
ment unveiled new antitrust enforcement guidelines for intellectual
property licensing that focus extensively on innovation competition.
I will divide this presentation into two parts. In the first part, I will
discuss the treatment of innovation in the new intellectual property
guidelines and recent government antitrust enforcement cases in the in-
tellectual property area. In the second part, I will focus on the subject
of collaborations among competitors, through joint ventures, in the re-
search and development and production of new products and processes.
I. INNOVATION MARKETS
The new intellectual property guidelines, which were issued on
April 6 of this year, announce the Justice Department's and Federal
Trade Commission's enforcement policy with respect to intellectual
property licensing. Intellectual property, of course, is an important
component of a great deal of productive activity today, and is often the
key asset of many collaborative ventures. The guidelines by their strict
terms discuss only the analysis that the government will use in review-
ing intellectual property licenses. But while the guidelines are literally
concerned with intellectual property licensing, their analytical frame-
work has a much broader reach, as it depicts the form of analysis that
the government now uses to analyze competition in markets in which
research and development or other innovative activity is a significant
component.
By way of preface, there is a natural tendency to think "high tech-
nology" when speaking of innovative activity. But it would be a mistake
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to think that innovation competition is a concern only for high technol-
ogy markets. While innovation issues have come up most often in cases
involving biotechnology companies, the most prominent Justice Depart-
ment case to address innovation competition involved heavy duty truck
transmissions. Innovative activity is not limited to any sphere of the
economy, and antitrust scrutiny of innovation competition similarly
goes beyond any sector of the economy.
Antitrust analysis is typically concerned with price competition.
Price is often described in antitrust cases as the central nervous system
of the economy and it has been the key concern of the antitrust laws
throughout their existence. That is still true today. When reviewing a
merger or acquisition, or analyzing a joint venture, the government's
principal concern is that the transaction would diminish price competi-
tion and lead to higher prices as a result.
Yet in recent years, the government has also shown an increasing
interest in competition in the sphere of research and development. Its
main concern has been that the pace of innovative activity may slacken
as competition in R&D becomes less intense. For example, suppose
that there are only three companies that make air conditioners, and I
want to stress that this is a purely hypothetical construct. These com-
panies compete with each other both in the price that they charge for
their products and in improvements that they make to their products
over time. It is at least plausible that combining two of the companies
through a merger may lead to a reduced innovative effort simply be-
cause there will be fewer competitors in the race. Just as the companies
might compete less vigorously in the price arena, because there are
fewer competitors who may undercut them, they might also devote less
effort to research and development to improve their products because
there are fewer rivals offering their own improvements. Of course, and
this is a key point, the government can attack this transaction solely on
the basis of its likely effects on price competition.
Anyone who has been in a business that engages in research and
development activity can think of several reasons why reducing the
number of competitors might not reduce competition in R&D. Cer-
tainly, in the case of efforts to develop radical innovations, the state-
ment that innovative activity diminishes as the number of competitors
diminishes is almost certainly not true. If you are seeking to devise a
cure to the common cold, the vast sums of money that await you if you
are successful are a powerful motivator to keep up the innovative effort
regardless of who else is competing with you. But there may be circum-
stances in which a key impetus for the effort to innovate is competitors'
innovative activities, and that is where the government is most likely to
be interested in innovation in its competitive analysis.
The theory behind the government's approach to innovation com-
petition under the new IP guidelines is that among other dimensions of
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competition, firms compete in research and development that may re-
sult in new or improved products or processes. The guidelines state that
where the capacity for research and development activity that likely
will produce innovation in a particular area is scarce and can be associ-
ated with identifiable specialized assets or characteristics of specific
firms, the antitrust agencies will consider the impact of companies' ac-
tivities on competition in a market for research and development or
innovation. In other words, in addition to, or in lieu of, examining the
impact of a transaction or particular conduct on prices, the agencies
will also look at the effects of the transaction or competitive practice on
innovation if there is reason to believe that the capacity to engage in a
particular type of R&D activity is confined to a small number of firms.
The capability is likely to be dependent either on preexisting experience
in a particular field of commerce or technology or on specialized R&D
facilities.
The areas in which antitrust concerns are likely to arise is in re-
search and development either for improving existing products or for
products that are near the commercialization stage. It is only when re-
search and development is at or near the stage of yielding commercial
products that it is possible to think of a predictable impact of a trans-
action on the pace of innovative activity. As we move back from ad-
vanced product-oriented research to more basic research, there are usu-
ally more participants in research activity and less of a predictable
impact of R&D on some output, or end product.
One general difficulty in this area is that the analysis of innovation
competition often focuses on markets that do not yet exist and there-
fore can take the antitrust analyst into the area of conjecture. Antitrust
in general has some conjectural qualities - when the government or a
court analyzes a merger, it must predict whether the merger will lead
to higher prices - and the tools that agencies and courts have at their
disposal are not precise scientific instruments. But we have some expe-
rience with observing markets under different circumstances of compe-
tition and therefore, at least a passable ability to make educated pre-
dictions of the effects of particular types of transactions or competitive
practices on competition.
In the area of innovation or R&D competition, our tools are more
crude. There is not yet a universally accepted consensus as to the kind
of market structure that best facilitates innovation, although many be-
lieve that a moderately concentrated structure - with the top four
firms holding perhaps a fifty percent aggregate market share - is
likely to be the most fertile ground for innovation. It is also recognized
that there are often benefits to a reduction in R&D competition in the
form of the elimination of costly duplication of parallel research paths.
We do not have a good handle on just how many independent research
paths we need to promote research and development competition, and
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the answer is likely to vary significantly from market to market
anyway.
All of these factors suggest that the government should tread very
carefully in the area of innovation competition. In 1984, Congress en-
acted the National Cooperative Research Act, or NCRA, to offer a
modest level of antitrust protection to collaborative activity in the area
of research and development by protecting R&D joint ventures that
register with the government from exposure to treble damages in anti-
trust law suits with respect to certain aspects of their activities. The
Act has been expanded since then to offer protection for production
joint ventures as well, and I will discuss it in a little more detail later
on. In the legislative history to the original NCRA, Congress suggested
that there should be no antitrust concerns where there are five or more
comparable research and development efforts underway, and this rule
of thumb has been widely accepted since then. The government's new
intellectual property guidelines adopt this view and indicate that no sig-
nificant antitrust issues would arise when there are five or more compa-
rable research and development efforts.
In reality, there has never been a case in which the government
has alleged effects on innovation competition when there were as many
as five competitors and it is hard to imagine when such a case would be
brought. Virtually all of the cases that the government has brought in
the area of innovation competition have been mergers in areas in which
only two or three firms were engaged in a particular type of research
and the transaction therefore would have reduced the number of inde-
pendent research efforts from three to two or two to one.
An example of this is the FTC's 1990 Roche Holdings case, which
concerned Roche's acquisition of Genentech. There the FTC charged
that an acquisition would put in the acquiring company's hands the two
leading technologies in three areas of genetic therapies that were then
under development. In two of the areas at issue, the FTC was con-
cerned with the loss of competition between an existing product and a
product under development. In these two markets, vitamin C and ther-
apeutics for human growth hormone deficiency, one party had a domi-
nant market share and the other was in advanced stages of develop-
ment of a competing technology. The consent order required the parties
to divest the technologies under development. In a third market, CD4-
based therapeutics, the FTC was concerned even more directly with
innovation competition. Genentech was allegedly the most advanced of
a limited number of companies developing CD4 while Roche had en-
gaged in CD4 research and development and had patent applications
pending on its CD4 products. The order required Roche to license its
CD4 patents to third parties.
In fact there are two types of concerns that underlay this case, as
well as the other cases that have been brought under the banner of
[Vol. 21:115 1995
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innovation competition. The first concern is with innovation competition
and the second is with pure price competition. If one company is about
to bring a product to market and the other may be a year behind it, it
is likely that price competition a year from now will be less vigorous if
the parties merge than it would be if they do not merge. And, at the
end of the day, virtually all of the cases that have been brought under
the banner of innovation competition have had this attribute: they in-
volved either a combination of one company that was already selling a
product and another that was close behind it in an advanced stage of
R&D or two companies in advanced stages, near commercialization, of
R&D.
So while some have expressed concern that the government is ex-
panding the antitrust laws by looking at innovation markets, I think
that there may be less here than meets the eye. The cases in which
innovation concerns had formed an independent basis for challenging a
transaction have been few and far between. In virtually every case in
which the government attacked a transaction based on its effects on
innovation competition, the parties were also head-on competitors in
the sale of existing products, and concerns about price competition with
respect to such products had been the key aspect of the challenge.
Having said that, there is a sense in which the Federal Trade
Commission has made innovation competition its theory du jour, so
that it is predictable now that virtually every FTC case involving a
corporate consolidation will allege effects on innovation competition.
Since November alone, the FTC has challenged transactions in part on
innovation concerns in the areas of a Rotavirus vaccine, joint implants,
anti-shoplifting devices, polypropylene technology, and intravascular ul-
trasound catheters. In each of the FTC's cases, the FTC permitted the
parties to proceed with the transaction, but conditioned the go-ahead
on the parties' licensing of intellectual property to their parties.
Unfortunately, there are signs that the FTC may be overreaching
in its quest to establish the theory of innovation markets. For example,
the FTC recently defined a market as consisting of the United States
and Canada for innovation in disposable antitheft tags. As a result,
European companies that were engaged in R&D in the relevant tech-
nology were excluded from the FTC's analysis, so that the transaction
under review appeared to have a more substantial impact on R&D
competition than it really did.
II. JOINT VENTURES
The government's cases involving innovation markets have tended
to involve mergers or acquisitions, but the context in which the innova-
tion market analysis is often likely to affect research and development
competition is collaboration among competitors through joint ventures.
Particularly in the area of transnational collaboration, the joint venture
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vehicle has proved useful in bringing to bear complementary skills and
innovative assets of international rivals to speed up the development of
new products. The joint venture format is useful because it may allow
companies that hold a different part of the answer to the technological
puzzle they are trying to solve, to join forces and advance toward a
solution to that puzzle. Firms could also join forces because they excel
in different aspects of the business - one company may have R&D
advantages while its partner may be particularly adept at production
technology. As the costs associated in investments in some new technol-
ogies have increased to levels that make it prudent to spread the risks,
joint ventures have become a common way to facilitate innovative
activity.
What is a joint venture? The term does not have a single, all-
encompassing definition. It can be and very often is applied to any type
of collaborative endeavor among independent companies to develop,
produce, or market products through a separate business entity. The
term can be applied to a loose collaboration among competing compa-
nies, which are more commonly referred to as strategic alliances or co-
operation agreements, as well as to free-standing business entities
through which the owners - which are separate companies - produce
and market a particular product.
I want to focus on the second, more formal type of activity - the
business entity through which separate firms, which very often will be
competitors with one another outside the framework of the collabora-
tion, join forces to develop or produce a product.
A joint venture can face antitrust review both before and after its
formation. At the formation stage, a joint venture may be subject to
review under Section 7 of the Clayton Act - the principal antitrust
statute governing mergers and acquisitions. Section 7 prohibits acquisi-
tions of assets or securities that may substantially lessen competition.
The federal government has an elaborate pre-merger notification pro-
cess under the Hart-Scott-Rodino Antitrust Improvements Act, which
requires certain mergers and acquisitions to be reported to the govern-
ment before their consummation, to give the government an opportu-
nity to review and challenge transactions before they take place and the
assets of the companies are commingled. This is the process that al-
lowed the FTC to challenge the transactions that I mentioned earlier.
Joint ventures that are established in corporate form may be sub-
ject to this prenotification procedure, depending on the size of the ven-
ture's parents and their financial contributions to the enterprise. But
joint ventures established in other forms, such as partnerships, are not
reportable to the government.
In addition to the possibility of this pre-merger review, joint ven-
tures face potential antitrust scrutiny throughout their existence. Joint
ventures, or agreements that govern their operations, may be chal-
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lenged at any time as agreements in restraint of trade under Section 1
of the Sherman Act.
Let us begin with the formation of joint ventures. Some joint ven-
tures are indistinguishable in their operation and effect from mergers of
their participants. Take for example two heavy vehicle manufacturers
that produce a wide range of products, including buses. Suppose that
the two companies form a joint venture to develop a new type of bus
and agree to develop, manufacture, and sell buses only through the
joint venture. In operation and effect, this is no different than a merger
of two bus manufacturers or an acquisition of one company's bus busi-
ness by the other. Before the transaction, both companies made buses;
after the transaction, only one company will make them. This transac-
tion will be seen as a merger.
Even when the collaboration is looser, such as where the compa-
nies agree to engage in joint research and development but will produce
the resulting products separately, any restriction on the independent
decisionmaking of the participants is subject to antitrust review. For
example, an R&D joint venture might prohibit participants from en-
gaging in similar collaborations with other companies. This type of re-
striction and other types of restrictions on the ability of joint venture
participants to engage in certain activities outside the joint venture will
be scrutinized for their competitive impact.
At this stage, before the consummation of the transaction, anti-
trust analysis looks at whether the proposed joint venture is likely to
diminish either actual or potential competition among the venture's
participants and thereby enable the participants to charge prices above
the level that would be charged in a competitive market. Where there
is a significant intellectual property component to the joint venture, the
transaction will also be scrutinized for its effects on innovation.
The most common concern at the pre-formation stage is that a
joint venture would reduce existing competition in a market by bring-
ing together into one enterprise two companies that would otherwise
compete with one another. The analysis begins by defining the "rele-
vant market" in which the parties compete. This has two components
- a product market and a geographic market. The product market
describes the range of products that compete with the product pro-
duced by the joint venturers. The geographic market describes the geo-
graphic locations to which purchasers would turn for alternatives to the
products of the joint venturers.
The product market at issue in most cases is a goods market, that
is a market for some real life product, be it a drug, a memory chip, or a
diesel engine. But in some cases, the product market may be an innova-
tion market. Where the participants in the joint venture are competi-
tors in some sphere of research and development and there are special-
ized assets that are associated with the R&D effort, the government's
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innovation market approach may be a relevant concern.
Having described the market, the analysis then seeks to evaluate
the transaction's likely effect within that market. It starts with concen-
tration levels - the more concentrated a market, the easier it is to
raise prices above the competitive level - but it also considers addi-
tional factors that bear on the ability of sellers to charge prices above
the competitive level. For example, the analysis will look at whether
products are homogeneous or differentiated because it is easier to en-
gage in tacit collusion when products are homogeneous. The analysis
will also consider how hard it is to enter the market in which the ven-
ture will compete. If it is easy to enter a market, even a seller with a
100% market share would not raise prices above the competitive level
because doing so would draw new entrants into the market and defeat
its price increase.
In cases with a significant research and development component,
the initial question will be whether the parties would have competed
with one another in the research and development sphere but for the
transaction. If they would not have competed in R&D, because one or
more would not have undertaken the activity without a collaborator,
that should be the end of the story - there can be no competitive
concerns when no competition would have existed in the absence of the
transaction.
If the parties would have engaged in separate R&D efforts but for
the transaction, the government will attempt to assess what technolo-
gies compete with those that the parties are developing, how many
firms compete in the development of the same or competing technolo-
gies, how many firms are capable of engaging in the relevant R&D,
even if they are not doing so already, and whether the creation of the
joint venture will reduce the number of independent technological
paths and the pace of innovative activity. Just listing these elements
underscores the point that I made earlier that this exercise is far from
an exact science. Based on prior experience, it is unlikely that a joint
venture would be challenged based on effects on R&D competition if
there are three or more additional independent and comparable R&D
efforts under way. Note that the intellectual property guidelines only
give assurances of no antitrust challenge where there are four addi-
tional independent R&D efforts in addition to that of the joint venture,
but it is hard to see how the government could convince a court that
there is a problem when a transaction reduces the number of indepen-
dent R&D efforts from five to four.
There can be real problems in determining what other research
and development efforts may exist in a particular field or which ones
are comparable to those that the parties would have undertaken in the
absence of the transaction. Research and development is carried out in
secrecy, in the privacy of research labs, so that information about who
(Vol. 21:115 1995
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is doing what is often sketchy. Compare this to goods markets, where
one can ascertain by examining a market who is selling what, and very
often to whom, and for how much.
One other issue that is considered at this stage is unique to joint
ventures. Where members of the joint venture continue to compete with
one another outside the venture, antitrust analysis may be concerned
with "spillover effects," which refers to the possibility that cooperation
within the venture may spill over to other markets in which the parties
are competitors and must continue to compete. For example, a joint
venture may facilitate the exchange of competitively sensitive informa-
tion. Suppose that two drug manufacturers set up a joint venture to
make a vaccine and the collaboration does not raise any concerns in
terms of its impact on price competition or R&D competition with re-
spect to the particular vaccine. The government may want to ensure
that joint venture will not be used as a mechanism to reduce competi-
tion in the sale of pharmaceuticals, in which the manufacturers con-
tinue to compete.
Where venture participants also compete in other markets in
which a joint venture between them would raise competitive concerns,
the antitrust agencies may require the venture to adopt procedures to
prevent the flow of competitively sensitive information between the par-
ties. It may require them to erect a "fire wall" between the vaccine
people and the pharmaceutical people or between the research groups
and the marketing groups to ensure that the joint venture will not be a
funnel through which the parties coordinate activities outside the joint
venture.
Let us move now to the antitrust considerations that affect the op-
eration of joint ventures. Here we will be talking about ancillary re-
straints, which are agreements that regulate the relationship between
co-venturers and the joint venture and among each other. Even a law-
fully formed joint venture, which otherwise survives the pre-formation
review described earlier, can violate the antitrust laws if it unreasona-
bly restricts competition among its participants. There are two princi-
pal areas of concern that could arise: agreements on price and agree-
ments that restrict competition with the joint venture. In the context of
joint ventures to engage in innovative activity, it is the latter type of
agreement, to restrict competition with the joint venture, that is the
relevant one and I will focus on that type of agreement in the time that
remains.
Ancillary restraints of joint ventures are evaluated under what an-
titrust lawyers call the rule of reason. Typically, analysis begins by as-
sessing the venture's market power, which involves asking the same
questions described in the discussion of the pre-formation review. This
requires defining a "relevant market" within which the venture com-
petes, determining the joint venture's market share, and assessing entry
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conditions in the market and other competitive factors that bear on the
venture's ability to charge prices above the level that would prevail in a
competitive market. Very often it is said that if the joint venture does
not possess market power, it is safe from antitrust attack, except with
respect to agreements on price. This view recently received strong con-
gressional support in the House Report to the National Cooperative
Production Amendments of 1993, which affirmed that "the absence of
market power among collaborating firms generally places their collabo-
ration beyond the pale of antitrust concern."
Let me illustrate this with an example. Let us say that two com-
puter manufacturers form a joint venture to supply on-board computers
for automobile engines. The two companies agree not to enter into any
other business to supply on-board computers for automobiles. This is a
common restriction found in joint venture agreements. Companies want
partners to devote their full support to the joint undertaking, to make
sure that the venture succeeds, and they also want to make sure that
they do not wind up giving their technology away to someone who is
going to compete against them. Let us assume that there are at least a
couple of dozen companies that either make on-board computers for
cars or have the capability and resources to do so. Because the venture
has no market power, this restraint is safe from antitrust challenge.
Suppose, on the other hand, that there were only a handful of
companies that have the capability of supplying on-board computers
for cars. In those circumstances, the court would examine whether the
restriction could harm competition by reducing the number of indepen-
dent sources of automobile computers. In theory, at least, if the re-
straint has the capacity to harm competition, that anticompetitive ca-
pacity is weighed against any efficiencies that the restraint might
enhance. For example, the restraint may be necessary to enable the
venture to compete, because it increases the incentive for the members
to promote the objectives of the joint venture and prevents them from
using the resources of the venture to compete against the venture.
In theory, again, the anticompetitive and beneficial effects are
weighed against one another. But this kind of weighing tends to be
more theoretical than real. In reality, courts seldom engage in this kind
of weighing, because they tend to find benefits (or efficiencies) where
they see no harmful potential and to reject claimed benefits or efficien-
cies where they find anticompetitive potential.
III. NATIONAL COOPERATIVE RESEARCH AND PRODUCTION ACT
I want to close by speaking briefly about the National Cooperative
Research and Production Act, or NCRPA. The NCRPA was enacted
to encourage collaborations among competitors in research and devel-
opment and production efforts. Under the NCRPA, joint ventures that
file an advance notification with the Federal Trade Commission and
[Vol. 21:115 1995
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Justice Department must be evaluated under the antitrust "rule of rea-
son" and are liable only for actual, rather than treble, damages for
violations of the antitrust law within the range of activities protected by
the statute. In reality, the rule of reason provision offers joint ventures
little or no additional protection beyond what they would have if they
did not file the required notification. The damages limitations is the
more significant benefit of filing a notification under the NCRPA.
To qualify for protection, activities of joint ventures must be pro-
tectable under the Act. Research and development, testing, and pro-
duction activities are protectable activities under the NCRPA. Unfor-
tunately, many common provisions in joint venture agreements cannot
be protected under the Act. For example, restrictions against co-ven-
turers competing with the venture by marketing products in competi-
tion with the joint venture are not protectable. The exchange of infor-
mation other than as reasonably necessary to carry out the purpose of
the venture is also not protectable, and what is reasonably necessary in
this context can often be a murky issue.
Production joint ventures are denied protection if they use "ex-
isting facilities" to produce a product "unless such use involves the pro-
duction of a new product or technology." Just what this means has
never been tested, but the imagination can run wild conjuring up litiga-
tion in which the issue in contention is whether a product or technology
was "new" enough to allow the use of an old factory.
Finally, production joint ventures are also denied NCRPA protec-
tion unless their principal production facilities are in the United States
and each person who controls a party to the venture is a U.S. person
(such as a U.S. corporation) or a foreign person whose country offers
parity of antitrust treatment to U.S. and domestic persons with respect
to participation in production joint ventures.
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